Neuroscience
Rare Infection Is Confirmed in 2nd Patient on M.S. Drug
By ANDREW POLLACK
The New York Times
Published: March 4, 2005
The makers of the multiple sclerosis drug Tysabri said yesterday that a second patient who used the drug had been confirmed to be suffering from a rare but deadly brain infection. The confirmed diagnosis is likely to somewhat diminish the chances that the drug will be able to return to the market.
[ ... Read the full article ... ]
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
Neuroscience
Tysabri (Natalizumab): An Additional Case
Rare Infection Is Confirmed in 2nd Patient on M.S. Drug
By ANDREW POLLACK
The New York Times
Published: March 4, 2005
The makers of the multiple sclerosis drug Tysabri said yesterday that a second patient who used the drug had been confirmed to be suffering from a rare but deadly brain infection. The confirmed diagnosis is likely to somewhat diminish the chances that the drug will be able to return to the market.
[ ... Read the full article ... ]
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...